Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04649359 · OUTCOME

Serum Concentration of Elranatamab

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
Nanograms per milliliter (ng/mL)
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Pre-dose on Day 1 of Cycle 4 and Pre-dose on Day 1 of Cycle 7

What was measured

Total and free concentrations of Elranatamab on Cycle 4 Day 1 (C4D1) and Cycle 7 Day 1 (C7D1) were reported in this outcome measure.

Analysis population: The pharmacokinetic (PK) analysis set was a subset of safety analysis set and included participants who had at least one post dose concentration measurement. Here, "Overall Number of Participants Analyzed" signifies maximum participants evaluable for this outcome measure.

Groups in this outcome

Cohort A

BCMA-naïve participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.

Cohort B

BCMA-exposed participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort A38
Cohort B21

Reported measurements

Total elranatamab concentrations (C4D1)

Analysis denominator · Participants

GroupSource count
Cohort A37
Cohort B21
Values in Nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Cohort A3110049Not reportedNot reportedNot reported
Cohort B2284063Not reportedNot reportedNot reported
Total elranatamab concentrations (C7D1)

Analysis denominator · Participants

GroupSource count
Cohort A29
Cohort B9
Values in Nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Cohort A3796047Not reportedNot reportedNot reported
Cohort B2988077Not reportedNot reportedNot reported
Free elranatamab concentrations (C4D1)

Analysis denominator · Participants

GroupSource count
Cohort A38
Cohort B21
Values in Nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Cohort A1909089Not reportedNot reportedNot reported
Cohort B16170114Not reportedNot reportedNot reported
Free elranatamab concentrations (C7D1)

Analysis denominator · Participants

GroupSource count
Cohort A29
Cohort B9
Values in Nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Cohort A3283081Not reportedNot reportedNot reported
Cohort B2988049Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        49
        value
        31100
      2. group Id
        OG001
        spread
        63
        value
        22840
    denoms
    1. counts
      1. group Id
        OG000
        value
        37
      2. group Id
        OG001
        value
        21
      units
      Participants
    title
    Total elranatamab concentrations (C4D1)
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        47
        value
        37960
      2. group Id
        OG001
        spread
        77
        value
        29880
    denoms
    1. counts
      1. group Id
        OG000
        value
        29
      2. group Id
        OG001
        value
        9
      units
      Participants
    title
    Total elranatamab concentrations (C7D1)
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        89
        value
        19090
      2. group Id
        OG001
        spread
        114
        value
        16170
    denoms
    1. counts
      1. group Id
        OG000
        value
        38
      2. group Id
        OG001
        value
        21
      units
      Participants
    title
    Free elranatamab concentrations (C4D1)
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        81
        value
        32830
      2. group Id
        OG001
        spread
        49
        value
        29880
    denoms
    1. counts
      1. group Id
        OG000
        value
        29
      2. group Id
        OG001
        value
        9
      units
      Participants
    title
    Free elranatamab concentrations (C7D1)
denoms
  1. counts
    1. group Id
      OG000
      value
      38
    2. group Id
      OG001
      value
      21
    units
    Participants
description
Total and free concentrations of Elranatamab on Cycle 4 Day 1 (C4D1) and Cycle 7 Day 1 (C7D1) were reported in this outcome measure.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    BCMA-naïve participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.
    id
    OG000
    title
    Cohort A
  2. description
    BCMA-exposed participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.
    id
    OG001
    title
    Cohort B
param Type
GEOMETRIC_MEAN
population Description
The pharmacokinetic (PK) analysis set was a subset of safety analysis set and included participants who had at least one post dose concentration measurement. Here, "Overall Number of Participants Analyzed" signifies maximum participants evaluable for this outcome measure.
reporting Status
POSTED
time Frame
Pre-dose on Day 1 of Cycle 4 and Pre-dose on Day 1 of Cycle 7
title
Serum Concentration of Elranatamab
type
SECONDARY
unit Of Measure
Nanograms per milliliter (ng/mL)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice